WALTHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic ...
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic ...
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company signed a memorandum of understanding (MOU) ...
Los Angeles, California, USA, November 15, 2022 – ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET TM) imaging agent and ...
Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in dose-escalation and dose-expansion phases of the study WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- DynamiCure, ...
OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Korea Health Industry Development Institute. The Company signed an ...
LOS ANGELES, Nov. 15, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results